VRPX (Virpax Pharmaceuticals) EPS (Basic) : $-128.94 (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Virpax Pharmaceuticals EPS (Basic)?

Virpax Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was $-5.69. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-128.94.

Virpax Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2024 was $-5.69. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-128.94.

Virpax Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2024 was $-5.69. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -128.94.

During the past 3 years, the average EPS without NRI Growth Rate was 46.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Virpax Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 46.10% per year. The lowest was -50.20% per year. And the median was -26.90% per year.

Virpax Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Virpax Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virpax Pharmaceuticals EPS (Basic) Chart

Virpax Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-240.62

-452.50

-462.25

-324.25

-71.00

Virpax Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-97.50	-68.75	-43.75	-10.75	-5.69

Virpax Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Virpax Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-12.067	-	0)	/	0.170
	=	-70.98

Virpax Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.39	-	0)	/	0.596
	=	-5.69

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-128.94

Virpax Pharmaceuticals (NAS:VRPX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Virpax Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Virpax Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Virpax Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virpax Pharmaceuticals Inc (NAS:VRPX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312

Website

https://www.virpaxpharma.com

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Executives

Sheila Mathias	officer: Chief Scientific Officer	1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Vinay Shah	officer: Chief Financial Officer	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Barbara Ruskin	director	C/O VIRPAX PHARMACEUTICALS, INC., 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jerrold Sendrow	director	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Eric Floyd	director	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Anthony P. Mack	director, 10 percent owner, officer: Chief Executive Officer	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Michael F Dubin	director	C/O VIRPAX PHARMACEUTICALS, 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Vanila Singh	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Gary S Jacob	director
Christopher Michael Chipman	officer: Chief Financial Officer	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Jeffrey Gudin	director, officer: Chief Medical Officer	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Thani Jambulingam	director	C/O VIRAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Gerald W Bruce	officer: EVP, Commercial Operations	NITROMED INC, 125 SPRING STREET, LEXINGTON MA 02421
Virpax Pharmaceuticals Llc	10 percent owner	C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380